Dyax Corp. (DYAX) Announces Presentation of KALBITOR® (ecallantide) Pediatric and Abdominal Attack Data at the American College of Allergy, Asthma and Immunology (ACAAI)
11/13/2012 10:23:29 AM
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that two poster presentations featuring updated KALBITOR® (ecallantide) data in pediatric patients with hereditary angioedema (HAE) and HAE patients with abdominal attacks were presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2012 Annual Scientific Meeting, held November 8-13, at the Anaheim Convention Center in Anaheim, CA. Both presentations pooled results from patients enrolled in four different clinical trials of ecallantide for the treatment of acute HAE attacks: DX-88/19, an open-label continuation study; EDEMA2®, an open-label, Phase 2 dose-ranging, repeat-dosing study; and EDEMA3® and EDEMA4®, two Phase 3 double-blind, placebo-controlled studies. KALBITOR is indicated for the treatment of acute attacks of HAE in patients 16 years of age and older.